Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Aseel Bin Sawad, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio & Fatema Turkistani. (2016) Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States. Current Medical Research and Opinion 32:11, pages 1783-1788.
Read now
Read now
Susan L. Kasser, Jesse V. Jacobs, Marley Ford & Timothy W. Tourville. (2015) Effects of balance-specific exercises on balance, physical activity and quality of life in adults with multiple sclerosis: a pilot investigation. Disability and Rehabilitation 37:24, pages 2238-2249.
Read now
Read now
Leonardo Koeser & Paul McCrone. (2013) Cost–effectiveness of natalizumab in multiple sclerosis: an updated systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 13:2, pages 171-182.
Read now
Read now
M. Heisen, M. J. Treur, W. S. van der Hel, S. T. F. M. Frequin, M. T. Groot & B. G. Verheggen. (2012) Fingolimod reduces direct medical costs compared to natalizumab in patients with relapsing–remitting multiple sclerosis in The Netherlands. Journal of Medical Economics 15:6, pages 1149-1158.
Read now
Read now
Annette Wundes, Theodore Brown, E. Jay Bienen & Craig I. Coleman. (2010) Contribution of intangible costs to the economic burden of multiple sclerosis. Journal of Medical Economics 13:4, pages 626-632.
Read now
Read now
Articles from other publishers (35)
Nneka C. Orji, Ingrid A. Cox, Leonard A. Jason, Gang Chen, Ting Zhao, Melissa J. Rogerson, Ryan M. Kelly, Karen Wills, Martin Hensher, Andrew J. Palmer, Barbara de Graaff & Julie A. Campbell. (2023) Assessing health state utilities for people with myalgic encephalomyelitis/chronic fatigue syndrome in Australia using the EQ-5D-5L, AQoL-8D and EQ-5D-5L-psychosocial instruments. Quality of Life Research.
Crossref
Crossref
Caroline K. Geiger, Danny Sheinson, Tu My To, David Jones & Nicole G. Bonine. (2023) Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab. Neurology and Therapy.
Crossref
Crossref
Holger Scheible, Martin Dyroff, Annick Seithel‐Keuth, Eleanor Harrison‐Moench, Nadra Mammasse, Andreas Port, Angelika Bachmann, Jennifer Dong, Jan Jaap Lier, William Tracewell & David Mitchell. (2021) Evobrutinib, a covalent Bruton’s tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. Clinical and Translational Science 14:6, pages 2420-2430.
Crossref
Crossref
Hasnat Ahmad, Ingrid van der Mei, Bruce Taylor, Ting Zhao, Qing Xia & Andrew J. Palmer. (2021) Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis?. Multiple Sclerosis and Related Disorders 54, pages 103138.
Crossref
Crossref
Steve Simpson-Yap, Pia Jelinek, Tracey Weiland, Nupur Nag, Sandra Neate & George Jelinek. (2021) Self-reported use of vitamin D supplements is associated with higher physical quality of life scores in multiple sclerosis. Multiple Sclerosis and Related Disorders 49, pages 102760.
Crossref
Crossref
Ricardo N. Alonso, Maria B. Eizaguirre, Leila Cohen, Cecilia Quarracino, Berenice Silva, Maria C. Pita, Cecilia Yastremiz, Sandra Vanotti & Orlando Garcea. (2021) Upper Limb Dexterity in Patients with Multiple Sclerosis. International Journal of MS Care 23:2, pages 79-84.
Crossref
Crossref
Kora Portilla-Cueto, Carlos Medina-Pérez, Ena Monserrat Romero-Pérez, José Aldo Hernández-Murúa, Claudia Eliza Patrocinio de Oliveira, Fernanda de Souza-Teixeira, Jerónimo J González-Bernal, Carolina Vila-Chã & José Antonio de Paz. (2020) Reference Values for Isometric, Dynamic, and Asymmetry Leg Extension Strength in Patients with Multiple Sclerosis. International Journal of Environmental Research and Public Health 17:21, pages 8083.
Crossref
Crossref
Hasnat Ahmad, Ingrid van der Mei, Bruce V. Taylor, Julie A. Campbell & Andrew J. Palmer. (2020) Measuring the health-related quality of life in Australians with multiple sclerosis using the assessment of quality of life-8-dimension (AQoL-8D) multi-attribute utility instrument. Multiple Sclerosis and Related Disorders 44, pages 102358.
Crossref
Crossref
Kathleen Healey, Rana Zabad, Lufei Young, Aubrie Lindner, Nancy Lenz, Renee Stewart & Mary Charlton. (2019) Multiple Sclerosis at Home Access (MAHA). International Journal of MS Care 21:3, pages 101-112.
Crossref
Crossref
Katarzyna Wiktorzak, Sylwia Szafraniec-Byryło, Urszula Jaworska, Melania Brzozowska, Waldemar Wierzba, Andrzej Śliwczyński & Donata Kurpas. (2019) Determinants of developing a pilot of coordinated care model for patients with multiple sclerosis in Poland. Medical Science Pulse 13:2, pages 11-17.
Crossref
Crossref
Sasitorn Siritho, Montarat Thavorncharoensap, Chalakorn Chanatittarat, Pakamas Pasogpakdee, Metha Apiwattanakul, Naraporn Prayoonwiwat, Siwaporn Chankrachang, Arthorn Riewpaiboon & Usa Chaikledkaew. (2018) Health utilities of patients with multiple sclerosis and neuromyelitis optica spectrum disorders in Thailand. Multiple Sclerosis and Related Disorders 24, pages 151-156.
Crossref
Crossref
Hanna Gyllensten, Andrius Kavaliunas, Kristina Alexanderson, Jan Hillert, Petter Tinghög & Emilie Friberg. (2018) Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Multiple Sclerosis Journal - Experimental, Translational and Clinical 4:3, pages 205521731878335.
Crossref
Crossref
Bernard M. J. Uitdehaag. (2018) Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis. CNS Drugs 32:6, pages 543-558.
Crossref
Crossref
Francisco J. Medina-Fernandez, Begoña M. Escribano, Evelio Luque, Javier Caballero-Villarraso, Jose L. Gomez-Chaparro, Montserrat Feijoo, Fe I. Garcia-Maceira, Alvaro Pascual-Leone, René Drucker-Colin & Isaac Tunez. (2018) Comparative of transcranial magnetic stimulation and other treatments in experimental autoimmune encephalomyelitis. Brain Research Bulletin 137, pages 140-145.
Crossref
Crossref
David Conradsson, Charlotte Ytterberg, Lena von Koch & Sverker Johansson. (2017) Changes in disability in people with multiple sclerosis: a 10-year prospective study. Journal of Neurology 265:1, pages 119-126.
Crossref
Crossref
Rafael Arroyo González, Mariko Kita, Heidi Crayton, Eva Havrdova, David H Margolin, Stephen L Lake & Gavin Giovannoni. (2016) Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal 23:10, pages 1367-1376.
Crossref
Crossref
Hasnat Ahmad, Bruce V Taylor, Ingrid van der Mei, Sam Colman, Beth A O’Leary, Monique Breslin & Andrew J Palmer. (2016) The impact of multiple sclerosis severity on health state utility values: Evidence from Australia. Multiple Sclerosis Journal 23:8, pages 1157-1166.
Crossref
Crossref
Vitalie Văcăraş, Zoltán Zsigmond Major & Anca Dana Buzoianu. (2017) Brain-derived neurotrophic factor levels under chronic natalizumab treatment in multiple sclerosis. A preliminary report. Neurologia i Neurochirurgia Polska 51:3, pages 221-226.
Crossref
Crossref
Juan Jose Yepes-Nuñez, Yuan Zhang, Feng Xie, Pablo Alonso-Coello, Anna Selva, Holger Schünemann & Gordon Guyatt. (2017) Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences' studies. Journal of Clinical Epidemiology 85, pages 21-31.
Crossref
Crossref
Olivia ErnstssonPetter TinghögKristina AlexandersonJan HillertKristina Burström. (2017) The External Validity of Mapping MSIS-29 on EQ-5D Among Individuals With Multiple Sclerosis in Sweden. MDM Policy & Practice 2:1, pages 238146831769280.
Crossref
Crossref
Gavin GiovannoniJeffrey A. CohenAlasdair J. ColesHans-Peter HartungEva HavrdovaKrzysztof W. SelmajDavid H. MargolinStephen L. LakeSusan M. KaupMichael A. PanzaraD. Alastair S. CompstonDoug Arnold, Jeffrey A. Cohen, Alasdair Coles, Alastair Compston, Christian Confavreux, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, Howard Weiner, Hillel Panitch, David Clifford, Jack Antel, Frederik Barkhof, David Snydman, Leslie DeGroot, Douglas Cines, Ralph D'Agostino, Benjamin Greenberg, Jörg Krauss, Volker Limmroth, Clyde Markowitz, Robert Naismith, David Tabby, Norma Haydee Deri, Karyn Boundy, Simon Broadley, Michael D. Dreyer, Suzanne Hodgkinson, John Owen King, Richard Macdonell, FAFRM RACP, Pamela Ann McCombe, Mark A. Paine, Stephen Reddel, Raymond Schwartz, Steve Vucic, MD. Karl Vass, PhD Dominique Dive, Benedicte D.P. Dubois, Christian Sindic, Dagoberto Callegaro, Maria Lucia B. Ferreira, Marcio Mena Barreto Martins, Charles Tilbery, Charles Ayotte, Donald G. Brunet, Mark S. Freedman, Francois Grand’Maison, Francois H. Jacques, Marcelo Kremenchutzky, Anthony L. Traboulsee, MD Licia Antonelli, Vesna Brinar, Mario Habek, Spomenka Kidemet Piskać, Zlatko Trkanjec, Anton Vladić, Ivana Kovarova, Ivan Rektor, Radomir Talab, Marta Vachova, Thor Petersen, Mads Ravnborg, Per Soelberg Sørensen, Michel Clanet, Pierre Clavelou, Jerome de Seze, Marc Debouverie, Gilles Edan, Catherine Lubetzki, Thibault Moreau, Patrick Vermersch, Karl Baum, Judith Haas, Bernhard Hemmer, U. Herrlinger, Wolfgang Köhler, Gunter Ochs, Martin Stangel, Hayrettin Tumani, Peter P. Urban, U. Klaus Zettl, Tjalf Ziemssen, Anat Achiron, Arnon Karni, Adi Vaknin Dembinsky, Antonio Bertolotto, Ruggero Capra, Giancarlo Comi, Luca Durelli, Angelo Ghezzi, Giovanni L. Mancardi, Maria Giovanna Marrosu, Carlo Pozzilli, Noemi Santos Caballero, Claudia Venzor Mendoza, Jesus Arturo Violante Villanueva, Raymond M.M. Hupperts, Erik van Munster, Wojciech Kozubski, Krzysztof Selmaj, Zbigniew Stelmasiak, Evgeniy R. Barantsevich, DMedSc, Anna N. Belova, Alexei N. Boyko, Evgeny I. Gusev, Nadezhda A. Malkova, Semen V. Perfiliev, Irina E. Poverennova, Alexander A. Skoromets, Igor D. Stolyarov, Eduard Z. Yakupov, Igor A. Zavalishin, Evica Dinčić, Jelena Drulović, Čongor Nadj, Gordana Tončev, Rafael Arroyo González, Guillermo Izquierdo Ayuso, Óscar Fernández, Xavier Montalbán, Jan Lycke, Anders Svenningsson, Tetyana O. Kobys, Tetyana I. Nehrych, Natalia P. Voloshyna, Gavin Giovannoni, David J. Rog, Neil James Scolding, Basil Sharrack, Nuhad E. Abou Zeid, Mark A. Agius, Ann Doan-Do Bass, G. Kim BigleyJrJr, Roberto Bomprezzi, Aaron Boster, Christine M. Boutwell, Tiffany J. Braley, Mark C. Cascione, Gary Clauser, Joanna A. Cooper, Heidi J. Crayton, Jeffrey Dunn, Keith R. Edwards, Stanton Elias, Bradley K. Evans, Mark H. Fletcher, Corey C. Ford, Elliot M. Frohman, Suzanne K. Gazda, Thomas Giancarlo, Jeffrey S. Gitt, Steven A. Glyman, Andrew Goodman, Christopher Gottschalk, Malcolm H. Gottesman, Erica M. Grazioli, Mark Gudesblatt, Ajay S. Gupta, Joseph Herbert, W. David Honeycutt, Bruce L. Hughes, Samuel F. Hunter, Todd J. Janus, Adil Javed, Davis E. Jones, Burk Jubelt, Lily Jung Henson, Omar Azhar Khan, Mariko Kita, Stephen Kirzinger, Stephen Krieger, Stanley J. Krolczyk, Christopher C. LaGanke, Enrico C. Lallana, Ellen S. Lathi, Neil S. Lava, Sharon G. Lynch, Bennett-Irving Machanic, Silva Markovic-Plese, David H. Mattson, Daniel D. Mikol, Aaron Miller, Tamara Ann Miller, Alireza Minagar, Galen W. Mitchell, Harold MosesJrJr, Donald Negroski, Gabriel Pardo, Mary Ann Picone, Jana Preiningerova, Kottil W. Rammohan, Claire S Riley, Peter N. Riskind, Syed A. Rizvi, Michael Rossen, Ted L. Rothstein, Vernon D. RoweIIIIII, Walter RoyalIIIIII, John D. Schaeffer, Christopher A. Sheppard, Richard A. Shubin, Scott L. Silliman, Barry A. Singer, Lee S. Stein, Brian Steingo, Herman C. Sullivan, Timothy K. Thoits, Ben W. Thrower, Cary L. Twyman, Anand G. Vaishnav, Stephen Gerard Vincent, Timothy Vollmer, Stephen R. Waldman, Leslie P. Weiner, Jeanette K. Wendt, Dean M. Wingerchuk, Sibyl E. Wray & Daniel R. Wynn. (2016) Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology 87:19, pages 1985-1992.
Crossref
Crossref
Annie Hawton & Colin Green. (2016) Health Utilities for Multiple Sclerosis. Value in Health 19:4, pages 460-468.
Crossref
Crossref
Fulya Mercan, Bilge Kara, Bedile Irem Tiftikcioglu, Emrah Mercan & Filiz Meryem Sertpoyraz. (2016) Effects of motor-motor and motor-cognitive tasks on balance in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders 7, pages 85-91.
Crossref
Crossref
Glenn Phillips, Shien Guo, Randall Bender, Eva Havrdová, Irina Proskorovsky & Timothy Vollmer. (2016) Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial. Multiple Sclerosis and Related Disorders 6, pages 66-72.
Crossref
Crossref
S.D. Newsome, S. Guo, A. Altincatal, I. Proskorovsky, E. Kinter, G. Phillips, X. You & G. Sabatella. (2015) Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis. Multiple Sclerosis and Related Disorders 4:4, pages 350-357.
Crossref
Crossref
Roberto Gatti, Andrea Tettamanti, Simone Lambiase, Paolo Rossi & Mauro Comola. (2014) Improving Hand Functional Use in Subjects with Multiple Sclerosis Using a Musical Keyboard: A Randomized Controlled Trial. Physiotherapy Research International 20:2, pages 100-107.
Crossref
Crossref
Rizwan Hamid, Clara Loveman, Jim Millen, Denise Globe, Catherine Corbell, Danielle Colayco, Sanja Stanisic & Dmitry Gultyaev. (2014) Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX®) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective. PharmacoEconomics 33:4, pages 381-393.
Crossref
Crossref
Lufei Young, Kathleen Healey, Mary Charlton, Kendra Schmid, Rana Zabad & Rebecca Wester. (2015) A home-based comprehensive care model in patients with Multiple Sclerosis: A study pre-protocol. F1000Research 4, pages 872.
Crossref
Crossref
Kathy FranklinEmma MatthewsKaren Mellors. (2014) A retrospective UK audit assessing the effect of the MySupport programme on patient persistence with MS treatment. British Journal of Neuroscience Nursing 10:3, pages 124-130.
Crossref
Crossref
Annie Hawton, James Shearer, Elizabeth Goodwin & Colin Green. (2013) Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis. Applied Health Economics and Health Policy 11:4, pages 331-341.
Crossref
Crossref
Maria K. Houtchens & Channa M. Kolb. (2012) Multiple sclerosis and pregnancy: therapeutic considerations. Journal of Neurology 260:5, pages 1202-1214.
Crossref
Crossref
Richard Nicholas & Tim Friede. (2012) Considerations in the design of clinical trials for relapsing multiple sclerosis. Clinical Investigation 2:11, pages 1073-1083.
Crossref
Crossref
A HawtonC GreenCJ TelfordDE WrightJP Zajicek. (2011) The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D. Multiple Sclerosis Journal 18:6, pages 853-861.
Crossref
Crossref
J Blahova DusankovaT KalincikT Dolezal, G Kobelt & E Havrdova. (2011) Cost of multiple sclerosis in the Czech Republic: The COMS study. Multiple Sclerosis Journal 18:5, pages 662-668.
Crossref
Crossref
F. Santoleri, P. Sorice, A. Carloni, F. De Vita, M. Belfiglio & A. Costantini. (2013) Farmacoutilizzazione e considerazioni economiche nella terapia della sclerosi multipla: il ruolo della Received Daily DosePharmacoutilization and economic considerations in the treatment of multiple sclerosis: the role of the Received Daily Dose. PharmacoEconomics Italian Research Articles 14:1, pages 39-45.
Crossref
Crossref